Home » Stocks » HOTH

Hoth Therapeutics, Inc. (HOTH)

Stock Price: $1.36 USD 0.05 (3.82%)
Updated May 14, 2021 4:00 PM EDT - Market closed
After-hours: $1.37 +0.01 (0.74%) May 14, 7:55 PM
Market Cap 32.47M
Revenue (ttm) n/a
Net Income (ttm) -9.63M
Shares Out 23.87M
EPS (ttm) -0.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $1.36
Previous Close $1.31
Change ($) 0.05
Change (%) 3.82%
Day's Open 1.27
Day's Range 1.27 - 1.38
Day's Volume 376,553
52-Week Range 1.27 - 4.96

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK, May 5, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has expanded its sponsored research agreement with Virginia Commonwealth Uni...

1 week ago - PRNewsWire

NEW YORK, May 3, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a patient-focused clinical-stage biopharmaceutical company, announced it intends to pursue development of its HT-KIT mRNA Fra...

1 week ago - PRNewsWire

NEW YORK, April 22, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is ple...

3 weeks ago - PRNewsWire

Hoth Therapeutics Inc (NASDAQ: HOTH) has reported that its novel anti-cancer therapeutic demonstrated positive results in humanized mast-cell neoplasm animal models for aggressive, mast cell-derived can...

3 weeks ago - Benzinga

NEW YORK, April 20, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, announced that its novel anti-cancer therapeutic exhibited hi...

3 weeks ago - PRNewsWire

NEW YORK, April 12, 2021 /PRNewswire/ -- Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, together with its manufacturing partner, has successfully completed t...

1 month ago - PRNewsWire

NEW YORK, April 6, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, announced that it has engaged Worldwide Clinical Trials ("Worldwide"), a full...

1 month ago - PRNewsWire

NEW YORK, April 5, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc.  (Nasdaq: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced that the Brazilian Patent Office has issued a...

1 month ago - PRNewsWire

Hoth Therapeutics Inc's (NASDAQ: HOTH) development partner, Voltron Therapeutics Inc has announced positive data from its second set of preclinical animal testing of HaloVax Self-Assembling Vaccine (SAV...

1 month ago - Benzinga

Shares of HOTH stock are blasting off on Tuesday morning after strong preclinical results from the firm's coronavirus treatment. The post HOTH Stock: The News That Has Biopharma Hoth Therapeutics Shooti...

1 month ago - InvestorPlace

Hoth Therapeutics Inc (NASDAQ: HOTH) soars after reporting new in vitro data for its lead peptide candidate for HT-002 to treat COVID-19. Data showed that HT-002 inhibited 50% of the cytopathic effect (...

1 month ago - Benzinga

NEW YORK, March 23, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a  biopharmaceutical company,  today announced new in vitro data demonstrating SARS-CoV-2 antiviral activity for its lead...

1 month ago - PRNewsWire

NEW YORK, March 19, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced an exclusive interview featuring Robb Knie, C...

1 month ago - PRNewsWire

Hoth Therapeutics Inc (NASDAQ: HOTH) has entered into a Research Agreement with the University of Cincinnati Research Institute to perform critical antimicrobial characterization studies with HT-006 as ...

1 month ago - Benzinga

NEW YORK, March 17, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a  biopharmaceutical company,  today announced entering into a Research Agreement with the University of Cincinnati Resea...

1 month ago - PRNewsWire

NEW YORK, March 11, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a  biopharmaceutical company,  today announced it has executed an agreement with REPROCELL Ltd., a contract research orga...

2 months ago - PRNewsWire

NEW YORK, March 10, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused clinical stage biopharmaceutical company, today announced the closing of its previously announced priva...

2 months ago - PRNewsWire

NEW YORK, March 8, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused clinical stage biopharmaceutical company, today announced that it has entered into a definitive agreemen...

2 months ago - PRNewsWire

NEW YORK, March 3, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused clinical stage biopharmaceutical company, today provided an update on preclinical study on HT-002 for th...

2 months ago - PRNewsWire

NEW YORK, March 1, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, is pleased to announce it has completed recruitment of Cohort 1 for its upcoming first in hum...

2 months ago - PRNewsWire

NEW YORK, Feb. 26, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has expanded its licensing agreement from North Carolina State University ...

2 months ago - PRNewsWire

NEW YORK, Feb. 25, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it retained RedChip Companies, Inc. ("RedChip") to lead its investor relation...

2 months ago - PRNewsWire

NEW YORK, Feb. 24, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has filed a provisional patent application with the United States Patent a...

2 months ago - PRNewsWire

NEW YORK, Feb. 23, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced today the successful completion of a pre-IND meeting with the U.S. Food and D...

2 months ago - PRNewsWire

Hoth Therapeutics Inc (NASDAQ: HOTH) plans to expand the development of the HT-003 active pharmaceutical ingredient (API) to pursue a new indication for the treatment of inflammatory bowel diseases (IBD...

2 months ago - Benzinga

NEW YORK, Feb. 18, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it intends to expand the development of the HT-003 active pharmaceutical...

2 months ago - PRNewsWire

NEW YORK, Feb. 10, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Scientific Advisory Board member, Michael Peter, Ph.D., published a whit...

3 months ago - PRNewsWire

NEW YORK, Feb. 8, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has signed an agreement with Camargo Pharmaceutical Services to facili...

3 months ago - PRNewsWire

NEW YORK, Jan. 28, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company, today announced extending a research collaboration agreement with W...

3 months ago - PRNewsWire

NEW YORK, Jan. 20, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced new in vitro data demonstrating the therapeutic potential of HT-003 to block ...

3 months ago - PRNewsWire

NEW YORK, Jan. 11, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced an agreement with Charles River Laboratories to initiate preclinical studies ...

4 months ago - PRNewsWire

NEW YORK, Jan. 4, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has entered into a Non-Exclusive Commercial Evaluation License Agreeme...

4 months ago - PRNewsWire

NEW YORK, Dec. 31, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has signed a production agreement for both GLP and GMP materials asso...

4 months ago - PRNewsWire

NEW YORK, Dec. 23, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced the request for a Pre-Investigational New Drug (IND) meeting to the U.S. Food...

4 months ago - PRNewsWire

NEW YORK, Dec. 10, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that is has received Human Research Ethics Committee (HREC) clearance to comm...

5 months ago - PRNewsWire

NEW YORK, Nov. 3, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced positive, statistically significant proof-of-concept preclinical data on its t...

6 months ago - PRNewsWire

NEW YORK, Nov. 2, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced key upcoming milestones towards the commercial development of the novel COVID-...

6 months ago - PRNewsWire

NEW YORK, Oct. 20, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that through its commercial licensing agreement with the University of Maryla...

6 months ago - PRNewsWire

NEW YORK, Sept. 24, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced completing testing to examine the ability of HT-003 to block acne pathogenic...

7 months ago - PRNewsWire

NEW YORK, Sept. 21, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has entered into a Sponsored Research Agreement ("SRA") with the Geo...

7 months ago - PRNewsWire

NEW YORK, Aug. 31, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc.

8 months ago - PRNewsWire

NEW YORK, Aug. 28, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc.

8 months ago - PRNewsWire

NEW YORK, Aug. 13, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc.

9 months ago - PRNewsWire

NEW YORK, July 31, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has executed a licensing agreement with Isoprene Pharmaceuticals, Inc.

9 months ago - PRNewsWire

NEW YORK, June 30, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced entering into a sponsored research agreement with Virginia Commonwealth Unive...

10 months ago - PRNewsWire

NEW YORK, June 15, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Scientific Advisory Board member and inventor of novel peptide COVID-19 ...

11 months ago - PRNewsWire

Wall Street sell-side analysts have issued buying recommendation ratings for shares of PDS Biotechnology Corp (NASDAQ:PDSB) and Hoth Therapeutics Inc (NASDAQ:HOTH), even though these stocks have fallen ...

Other stocks mentioned: PDSB
11 months ago - GuruFocus

NEW YORK, June 8, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice...

11 months ago - PRNewsWire

NEW YORK, May 27, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ: HOTH), a biopharmaceutical company, announced today the closing of its previously announced underwritten...

11 months ago - PRNewsWire

NEW YORK, May 22, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Michael H. Peters, Ph.D., has joined the company's Scientific Advisory Bo...

11 months ago - PRNewsWire

About HOTH

Hoth Therapeutics, Inc., a biopharmaceutical company, focuses on developing therapies for dermatological disorders. The company focuses on therapies for patients suffering from indications, including eczema, chronic wounds, psoriasis, asthma, and acne. Its pipeline portfolio includes HT-001, a topical formulation for the treatment of mild to moderate rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor (EGFR) inhibitor therapy; HT-002 to treat illness associated with SA... [Read more...]

Industry
Biotechnology
IPO Date
Feb 15, 2019
Stock Exchange
NASDAQ
Ticker Symbol
HOTH
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for HOTH stock is "Strong Buy" and the 12-month stock price forecast is 10.00.

Price Target
$10.00
Analyst Consensus: Strong Buy